Ireland's Amryt Aiming For Success Stateside
Files For NASDAQ Listing
Executive Summary
With two revenue-generating products already on the market and Phase III data pending on Filsuvez for epidermolysis bullosa, CEO Joe Wiley has told Scrip that a US listing will give Amryt more visibility and credibility when it comes to future licensing and acquisition possibilities.
You may also be interested in...
Amryt's Wings Clipped By Delay For Butterfly Skin Drug Decision
The Irish firm needs to give regulators in the US more information on its epidermolysis bullosa therapy but is confident of address those requests from its "existing data within the time periods required," according to CEO Joe Wiley.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.